论文部分内容阅读
Objective To investigate the correlation between BRAF V600 E mutation and anti-epidermal growth factor receptor(EGFR) monoclonal antibodies(Mo Abs) therapeutic effects in metastatic colorectal cancer. Methods Studies were included into meta-analysis to investigate the association between BRAF V600 E mutation and clinical outcome in metastatic colorectal cancer patients treated with anti-EGFR Mo Abs. Results A total of 7 studies were included in this meta-analysis. The 7 studies included 1352 patients in total, sample sizes ranged from 67 to 493. Objective response rate(ORR), progression-free survival(PFS) and overall survival(OS) were collected from included studies and were used to assess the strength of the relation. In patients with wild-type KRAS, the pooled odds ratio for ORR of mutant BRAF over wild-type BRAF was 0.27(95% CI=0.10-0.70). BRAF mutation predicted a deterioration in PFS and OS in wild-type KRAS patients treated with anti-EGFR Mo Abs(hazard ratio=2.78, 95% CI=1.62-4.76; hazard ratio=2.54, 95% CI=1.93-3.32). Conclusion BRAF V600 E mutation is related to lack of response and worse survival in wild-type KRAS metastatic colorectal cancer patients treated with anti-EGFR Mo Abs.
Objective To investigate the correlation between BRAF V600 E mutation and anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (Mo Abs) therapeutic effects in metastatic colorectal cancer. Methods Studies were included into meta-analysis to investigate the association between BRAF V600 E mutation and clinical outcome in metastatic colorectal cancer patients treated with anti-EGFR Mo Abs. Results A total of 7 studies were included in this meta-analysis. The 7 studies included 1352 patients in total, sample sizes ranged from 67 to 493. Objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were collected from included studies and were used to assess the strength of the relation. In patients with wild-type KRAS, the pooled odds ratio for ORR of mutant BRAF BRAF mutation predicted a deterioration in PFS and OS in wild-type KRAS patients treated with anti-EGFR Mo Abs (hazard ratio = 2.78, 95% CI = 1.62 -4.7 6; hazard ratio = 2.54, 95% CI = 1.93-3.32). Conclusion BRAF V600 E mutation is related to lack of response and worse survival in wild-type KRAS metastatic colorectal cancer patients treated with anti-EGFR Mo Abs.